Versor Investments LP Has $1.28 Million Stock Holdings in Masimo Co. (NASDAQ:MASI)

Versor Investments LP raised its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 81.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,591 shares of the medical equipment provider's stock after acquiring an additional 4,313 shares during the quarter. Versor Investments LP's holdings in Masimo were worth $1,279,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Thrivent Financial for Lutherans grew its position in Masimo by 42.1% during the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider's stock valued at $153,314,000 after acquiring an additional 360,497 shares during the period. Point72 Asset Management L.P. grew its position in Masimo by 107.8% during the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider's stock valued at $85,347,000 after acquiring an additional 351,523 shares during the period. Bamco Inc. NY purchased a new stake in Masimo during the first quarter valued at about $50,781,000. Farallon Capital Management LLC grew its position in Masimo by 13.6% during the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider's stock valued at $218,742,000 after acquiring an additional 177,914 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Masimo by 45.9% during the second quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider's stock valued at $66,201,000 after acquiring an additional 165,257 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Trading Down 0.5 %

MASI stock traded down $0.78 during mid-day trading on Tuesday, reaching $160.85. 485,338 shares of the stock traded hands, compared to its average volume of 680,489. The company has a current ratio of 2.01, a quick ratio of 1.15 and a debt-to-equity ratio of 0.50. Masimo Co. has a 52-week low of $86.94 and a 52-week high of $173.90. The company has a market cap of $8.61 billion, a P/E ratio of 110.69 and a beta of 0.97. The stock's fifty day moving average is $134.41 and its 200-day moving average is $126.12.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share. As a group, sell-side analysts expect that Masimo Co. will post 4.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company upped their target price on Masimo from $160.00 to $171.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 6th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. BTIG Research boosted their price target on Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Piper Sandler boosted their price target on Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, Raymond James upgraded Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price target on the stock in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Masimo currently has a consensus rating of "Moderate Buy" and an average price target of $163.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.